NCT05214014

Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells

Treatment of Patients With Systemic Sclerosis With Autologous Regulatory Т-cells

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Treatment of patients with systemic sclerosis with autologous regulatory Т-cells

Detailed description

Considering the fact that a decrease in the content and functional activity of T-reg plays an important role in the immunopathogenesis of many systemic diseases of the connective tissue, the use of a large amount of T-reg can have a therapeutic effect.

Conditions

• Systemic Sclerosis

Interventions

Type	Name	Description
BIOLOGICAL	Autologous Regulatory Т-cells	Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
OTHER	Standard treatment according to the clinical protocols	Standard treatment of Systemic Sclerosis according to the clinical protocols

Timeline

• Start date: 2022-09-01
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2022-01-28
• Last updated: 2022-09-14

Locations

1 site across 1 country: Belarus